ArticleCancers2019

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.

Nicola Amodio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.